Advertisement

International Ophthalmology

, Volume 37, Issue 1, pp 215–219 | Cite as

Occurrence of intraocular air bubbles during intravitreal injections for retinopathy of prematurity

  • Emine Alyamac Sukgen
  • Murat Gunay
  • Yusuf Kocluk
Original Paper
  • 283 Downloads

Abstract

This study aims to present five cases with retinopathy of prematurity (ROP) who were found to have intraocular air bubbles after intravitreal injection (IVI) treatment. The medical records of 148 infants who underwent IVI for ROP were retrospectively reviewed and the ones who demonstrated post-injection intraocular air bubble formation were recruited. Of the 148 patients (31 babies received ranibizumab, 20 babies received aflibercept, 97 babies received bevacizumab), five were found to have intraocular air bubbles right after the IVI. Two infants received intravitreal ranibizumab and three received intravitreal bevacizumab injections. Although intraocular pressure increased temporarily, no intraocular sterile or infective reactions were observed in the postoperative period. The air bubble was found to resorb spontaneously within 72 h. The occurrence rate of the intravitreal air bubbles in our series was 3.37 % despite previously not been reported in the literature. Due to the intravitreal air injection risk, it is important to be more careful while preparing the intravitreal medication before treatment in premature babies.

Keywords

Bevacizumab Ranibizumab Intravitreal air bubbles Intravitreal treatment Retinopathy of prematurity 

Notes

Funding

The authors did not receive any financial support from any public or private sources. The authors have no financial or proprietary interest in a product, method or material described herein.

References

  1. 1.
    Lad EM, Hernandez-Boussard T, Morton JM, Moshfeghi DM (2009) Incidence of retinopathy of prematurity in the United States: 1997 through 2005. Am J Ophthalmol 148(3):451–458CrossRefPubMedGoogle Scholar
  2. 2.
    Cryotherapy for Retinopathy of Prematurity Cooperative Group (1990) Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome—structure and function. Arch Ophthalmol 108(10):1408–1416CrossRefGoogle Scholar
  3. 3.
    Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121(12):1684–1694CrossRefGoogle Scholar
  4. 4.
    Mintz-Hittner HA, Kennedy KA, Chuang AZ, Beat-rop Cooperative Group (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364(7):603–615CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lai TY, Liu S, Das S, Lam DS (2015) Intravitreal injection-technique and safety. Asia Pac J Ophthalmol (Phila) 4:321–328CrossRefGoogle Scholar
  6. 6.
    Kuniyoshi K, Sugioka K, Sakuramoto H, Kusaka S, Wada N, Shimomura Y (2014) Intravitreal injection of bevacizumab for retinopathy of prematurity. Jpn J Ophthalmol 58(3):237–243CrossRefPubMedGoogle Scholar
  7. 7.
    Wu WC, Kuo HK, Yeh PT, Yang CM, Lai CC, Chen SN (2013) An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan. Am J Ophthalmol 155(1):150–158CrossRefPubMedGoogle Scholar
  8. 8.
    Somner JE, Mansfield D (2009) In advertent injection of intravitreal air during intravitreal Lucentis injection for wet age-related macular degeneration: an un described complication. Eye 23(8):1744CrossRefPubMedGoogle Scholar
  9. 9.
    Castellanos MA, Schwartz S, García-Aguirre G, Quiroz-Mercado H (2013) Short-term out come after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol 97(7):816–819CrossRefPubMedGoogle Scholar
  10. 10.
    Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR (2015) Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology 122(5):1008–1015CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Yetik H, Gunay M, Sirop S, Salihoglu Z (2015) Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity—27 month follow-up results from Turkey. Graefes Arch Clin Exp Ophthalmol 253(10):1677–1683CrossRefPubMedGoogle Scholar
  12. 12.
    Shima C, Sakaguchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, Sawa M, Tsujikawa M, Kusaka S, Tano Y (2008) Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 86(4):372–376CrossRefPubMedGoogle Scholar
  13. 13.
    Yun C, Oh J, Hwang SY, Kim SW, Huh K (2015) Subconjunctival hemorrhage after intravitreal injection of anti-vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 253(9):1465–1470CrossRefPubMedGoogle Scholar
  14. 14.
    Erdogan G, Gunay BO, Unlu C, Gunay M, Ergin A (2015) Management of iatrogenic crystalline lens injury occurred during intravitreal injection. Int Ophthalmol: 1–4 [Epub ahead of print]Google Scholar
  15. 15.
    Weismann LE, Stoll BJ, Kueser TJ, Rubio TT, Frank CG, Heiman HS et al (1994) Intravenous immune globulin prophylaxis of late-onset sepsis in premature neonates. J Pediatr 125:922–930CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  • Emine Alyamac Sukgen
    • 1
  • Murat Gunay
    • 2
  • Yusuf Kocluk
    • 1
  1. 1.Eye DepartmentAdana Numune Training and Research HospitalAdanaTurkey
  2. 2.Turkish Republic Ministry of Health Zeynep Kamil Gynecology and Pediatrics Education and Research HospitalUskudarTurkey

Personalised recommendations